|
|
| | Src Inhibitor 3 Basic information |
| Product Name: | Src Inhibitor 3 | | Synonyms: | Src Inhibitor 3;1H-Indazole-3-carboxamide, N-[3-chloro-4-[[(6-methoxypyrazolo[1,5-a]pyridin-3-yl)carbonyl]amino]phenyl]-1-[1-(3-cyano-3-methyl-1-oxobutyl)-4-piperidinyl]-5-fluoro-;Src,Src Inhibitor3,inhibit,Src Inhibitor 3,Src Inhibitor-3,Inhibitor;Src Inhibitor 3, 10 mM in DMSO;N-[3-chloro-4-[(6-methoxypyrazolo[1,5-a]pyridine-3-carbonyl)amino]phenyl]-1-[1-(3-cyano-3-methylbutanoyl)piperidin-4-yl]-5-fluoroindazole-3-carboxamide | | CAS: | 2380027-49-4 | | MF: | C34H32ClFN8O4 | | MW: | 671.12 | | EINECS: | | | Product Categories: | | | Mol File: | 2380027-49-4.mol |  |
| | Src Inhibitor 3 Chemical Properties |
| density | 1.43±0.1 g/cm3(Predicted) | | pka | 10.20±0.70(Predicted) | | form | Solid | | color | Light yellow to yellow |
| | Src Inhibitor 3 Usage And Synthesis |
| Uses | CSK-IN-1 (compound 13) is a potent, orally active c-terminal Src kinase (CSK) with IC50 values below 3 nM and 4 nM in CSK HTRF and Caliper assay, respectively. CSK-IN-1 shows the ability to increase T cell proliferation induced by T cell receptor signaling[1]. | | in vivo | CSK-IN-1 (compound 13) reduces inhibitory LCK phosphorylation in vivo upon oral dosing and shows the ability to enhance T cell activation in response to antigen stimulation[1]. | | References | [1] O'Malley DP, et al. Discovery of Pyridazinone and Pyrazolo[1,5-a]pyridine Inhibitors of C-Terminal Src Kinase. ACS Med Chem Lett. 2019 Sep 25;10(10):1486-1491. DOI:10.1021/acsmedchemlett.9b00354 |
| | Src Inhibitor 3 Preparation Products And Raw materials |
|